[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"magnesium-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:magnesium-deficiency":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100618972","magnesium-in-gastrointestinal-disease-100618972",false,"NCT07338565","Magnesium in Gastrointestinal Disease","Magnesium Status in Patients With Gastrointestinal Disease","MAGIC","Inclusion Criteria:\n\n\\- Age 18 or older, mentally competent, and able to understand Danish.\n\nGroup 1:\n\n\\- Diagnosed with IBD (DK50X, Crohn's disease, or DK51X, ulcerative colitis), ileostomy (DZ932) or bile acid diarrhoea (DSK908B) (Se-HCAT scintigraphy showing residual activity \\\u003C10%).\n\nGroup 2:\n\n\\- Healthy individuals.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Use of oral magnesium supplements for more than 2 weeks before inclusion.",true,"ALL","18 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","Individuals with gastrointestinal diseases - such as Crohn's disease, ulcerative colitis, ileostomy, or bile acid diarrhoea - are at increased risk of magnesium deficiency. Magnesium is a vital mineral that supports many essential functions in the body, including muscle contraction, nerve signalling, heart rhythm, and bone health. Deficiency may contribute to fatigue, muscle cramps, abnormal heart rhythms, and reduce the quality of life.\n\nThe purpose of this study is to investigate the prevalence of magnesium deficiency in individuals with these conditions and to identify the most accurate and practical methods for assessing magnesium status in clinical care.\n\nAlthough plasma magnesium is commonly used in routine blood tests, it represents only about 1% of the body's total magnesium and may not reflect true magnesium levels within cells or tissues. Hence, this study compares several different ways of measuring magnesium, including:\n\n* Plasma magnesium\n* Magnesium levels in red and white blood cells (PBMC, RBC, and buffy coat)\n* Magnesium levels in muscle tissue (via biopsy)\n* A magnesium retention test, based on how much magnesium is excreted after an infusion\n\nThe study includes four groups:\n\n1. Patients with inflammatory bowel disease.\n2. Patients with an ileostomy.\n3. Patients with bile acid diarrhoea.\n4. Healthy individuals (control group).\n\nAll participants will provide blood and urine samples, and some may undergo optional biopsies of muscle or intestinal tissue. Participants will also complete questionnaires and undergo tests of muscle strength and body composition.\n\nThe findings are expected to enhance the understanding and detection of magnesium deficiency in patients with gastrointestinal diseases and to aid in the development of more effective tools for identifying and treating this common yet often overlooked condition.",[26,27,28,29,30,31,32,33,34,35,36,37],"Colitis Ulcerosa","Colitis Ulcerative","Crohns Disease","Morbus Crohn","Ileostomy - Stoma","Ileostoma","Ileostomies","Bile Acid Diarrhea","Bile Acid Malabsorption","Magnesium Deficiency","Magnesium Level","Magnesium","RECRUITING","2026-01-05",{"date":41,"type":42},"2026-01-14","ACTUAL",{"date":44,"type":42},"2025-11-03",{"date":46,"type":22},"2027-12-01",{"name":48,"class":49},"University of Aarhus","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":17,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":66,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":50},"100591378","effectiveness-of-qualia-magnesium-supplementation-on-rbc-magnesium-levels-100591378","NCT06979648","Effectiveness of Qualia Magnesium+® Supplementation on RBC Magnesium Levels","Effectiveness of Qualia Magnesium+® Supplementation on RBC Magnesium Levels: A Randomized Double-Blind Parallel Trial","Inclusion Criteria:\n\n* Provide voluntary, written, informed consent to participate in the study\n* Agree to provide a valid cell phone number and are willing to receive communications through text\n* Can read and write English\n* Willing to complete questionnaires, records, and diaries associated with the study.\n* Male and female participants aged 21 years and older\n* Willing and able to visit a local blood draw facility for required blood sample collections\n* Live within 20 miles of a suitable blood draw facility (such as Quest)\n* RBC Magnesium levels below 6.0 mg\u002FdL\n* Willing to not consume any supplements containing magnesium starting about 2 weeks prior to the baseline magnesium blood test and continuing through the intervention period.\n* Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly with the exception of those containing magnesium\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial\n* Known food intolerances\u002Fallergy to any ingredients in the product\n* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer\n* Having had a significant cardiovascular event in the past 6 months\n* Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines\n* On immunosuppressive therapy\n* Individuals who were deemed incompatible with the test protocol\n* Adults lacking capacity to consent","21 Years",{"count":60,"type":22},100,"INTERVENTIONAL",[63],"NA","This is a randomized, double-blind, placebo-controlled parallel trial designed to evaluate the effectiveness of Qualia Magnesium+® supplementation on red blood cell (RBC) magnesium levels in adults aged 21 and older. Approximately 100 participants with baseline RBC magnesium levels below 6.0 mg\u002FdL will be randomly assigned to receive either Qualia Magnesium+ or a placebo. Participants will take 2 capsules daily in the evening, with or without food, for a duration of 12 weeks. The primary outcome is the between-group change in RBC magnesium levels from baseline to Week 12. Secondary outcomes include assessments of sleep quality, perceived stress, magnesium status, and safety and tolerability. Data collection will occur through lab bloodwork and electronic questionnaires.",[35],[67,68],"Magnesium supplementation","magnesium","NOT_YET_RECRUITING","2025-05-13",{"date":72,"type":42},"2025-05-20",{"date":74,"type":22},"2025-05-21",{"date":76,"type":22},"2025-09-21",{"name":78,"class":79},"Qualia Life Sciences","INDUSTRY"]